255 related articles for article (PubMed ID: 23098607)
1. Carbonic anhydrase IX as a target for metastatic disease.
Gieling RG; Williams KJ
Bioorg Med Chem; 2013 Mar; 21(6):1470-6. PubMed ID: 23098607
[TBL] [Abstract][Full Text] [Related]
2. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII.
Guler OO; De Simone G; Supuran CT
Curr Med Chem; 2010; 17(15):1516-26. PubMed ID: 20166929
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumor-associated carbonic anhydrase IX in cancer therapy.
Thiry A; Dogné JM; Masereel B; Supuran CT
Trends Pharmacol Sci; 2006 Nov; 27(11):566-73. PubMed ID: 16996620
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.
Ward C; Meehan J; Mullen P; Supuran C; Dixon JM; Thomas JS; Winum JY; Lambin P; Dubois L; Pavathaneni NK; Jarman EJ; Renshaw L; Um IH; Kay C; Harrison DJ; Kunkler IH; Langdon SP
Oncotarget; 2015 Sep; 6(28):24856-70. PubMed ID: 26259239
[TBL] [Abstract][Full Text] [Related]
5. N-β-glycosyl sulfamides are selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
Rodríguez OM; Maresca A; Témpera CA; Bravo RD; Colinas PA; Supuran CT
Bioorg Med Chem Lett; 2011 Aug; 21(15):4447-50. PubMed ID: 21723123
[TBL] [Abstract][Full Text] [Related]
6. Carbonic anhydrase IX inhibitors in cancer therapy: an update.
Supuran CT; Winum JY
Future Med Chem; 2015; 7(11):1407-14. PubMed ID: 26230880
[TBL] [Abstract][Full Text] [Related]
7. Glycosidic carbonic anhydrase IX inhibitors: a sweet approach against cancer.
Winum JY; Colinas PA; Supuran CT
Bioorg Med Chem; 2013 Mar; 21(6):1419-26. PubMed ID: 23199483
[TBL] [Abstract][Full Text] [Related]
8. Structural insights into carbonic anhydrase IX isoform specificity of carbohydrate-based sulfamates.
Moeker J; Mahon BP; Bornaghi LF; Vullo D; Supuran CT; McKenna R; Poulsen SA
J Med Chem; 2014 Oct; 57(20):8635-45. PubMed ID: 25254302
[TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain.
Zatovicova M; Jelenska L; Hulikova A; Csaderova L; Ditte Z; Ditte P; Goliasova T; Pastorek J; Pastorekova S
Curr Pharm Des; 2010; 16(29):3255-63. PubMed ID: 20819068
[TBL] [Abstract][Full Text] [Related]
10. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents.
Winum JY; Rami M; Scozzafava A; Montero JL; Supuran C
Med Res Rev; 2008 May; 28(3):445-63. PubMed ID: 17880011
[TBL] [Abstract][Full Text] [Related]
11. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
Lock FE; McDonald PC; Lou Y; Serrano I; Chafe SC; Ostlund C; Aparicio S; Winum JY; Supuran CT; Dedhar S
Oncogene; 2013 Oct; 32(44):5210-9. PubMed ID: 23208505
[TBL] [Abstract][Full Text] [Related]
12. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts.
Gieling RG; Babur M; Mamnani L; Burrows N; Telfer BA; Carta F; Winum JY; Scozzafava A; Supuran CT; Williams KJ
J Med Chem; 2012 Jun; 55(11):5591-600. PubMed ID: 22621623
[TBL] [Abstract][Full Text] [Related]
13. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives.
Ahlskog JK; Dumelin CE; Trüssel S; Mårlind J; Neri D
Bioorg Med Chem Lett; 2009 Aug; 19(16):4851-6. PubMed ID: 19615903
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of carbonic anhydrase isoforms I, II, IX and XII with novel Schiff bases: identification of selective inhibitors for the tumor-associated isoforms over the cytosolic ones.
Sarikaya B; Ceruso M; Carta F; Supuran CT
Bioorg Med Chem; 2014 Nov; 22(21):5883-90. PubMed ID: 25267005
[TBL] [Abstract][Full Text] [Related]
15. Design of a carbonic anhydrase IX active-site mimic to screen inhibitors for possible anticancer properties.
Genis C; Sippel KH; Case N; Cao W; Avvaru BS; Tartaglia LJ; Govindasamy L; Tu C; Agbandje-McKenna M; Silverman DN; Rosser CJ; McKenna R
Biochemistry; 2009 Feb; 48(6):1322-31. PubMed ID: 19170619
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel 4-(4-oxo-2-arylthiazolidin-3-yl)benzenesulfonamides as selective inhibitors of carbonic anhydrase IX over I and II with potential anticancer activity.
Suthar SK; Bansal S; Lohan S; Modak V; Chaudhary A; Tiwari A
Eur J Med Chem; 2013 Aug; 66():372-9. PubMed ID: 23827177
[TBL] [Abstract][Full Text] [Related]
17. [Progress in the study of carbonic anhydrase inhibitors as potential anticancer drugs].
Guo J; Li FR; Liu Y; Cheng MS
Yao Xue Xue Bao; 2013 Nov; 48(11):1637-43. PubMed ID: 24475699
[TBL] [Abstract][Full Text] [Related]
18. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
Winum JY; Dogné JM; Casini A; de Leval X; Montero JL; Scozzafava A; Vullo D; Innocenti A; Supuran CT
J Med Chem; 2005 Mar; 48(6):2121-5. PubMed ID: 15771455
[TBL] [Abstract][Full Text] [Related]
19. Saccharin: a lead compound for structure-based drug design of carbonic anhydrase IX inhibitors.
Mahon BP; Hendon AM; Driscoll JM; Rankin GM; Poulsen SA; Supuran CT; McKenna R
Bioorg Med Chem; 2015 Feb; 23(4):849-54. PubMed ID: 25614109
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of carbonic anhydrase IX: a new strategy against cancer.
Winum JY; Scozzafava A; Montero JL; Supuran CT
Anticancer Agents Med Chem; 2009 Jul; 9(6):693-702. PubMed ID: 19601749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
